Unknown

Dataset Information

0

Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study.


ABSTRACT:

Introduction

The EMBRACE study (Clinical Trials No. NCT02462759) evaluated nusinersen in infants/children with infantile- or later-onset spinal muscular atrophy (SMA) who were ineligible for the ENDEAR and CHERISH studies.

Methods

Participants were randomized to intrathecal nusinersen (12-mg scaled equivalent dose; n = 14) or sham procedure (n = 7) in part 1 (~14 months) and subsequently received open-label nusinersen for ~24 months in part 2 of the study.

Results

Part 1 was stopped early after the demonstration of motor function benefit with nusinersen in ENDEAR. There were no nusinersen-related adverse events (AEs) and no study discontinuations due to nusinersen-related AEs. The most common AEs included pyrexia, cough, pneumonia, and upper respiratory tract infections. Motor milestone responder rates were higher in those receiving nusinersen at last available assessment (93%) than in those receiving sham procedure in part 1 (29%) or transitioned from sham to nusinersen in part 2 (83%). This functional improvement was observed despite the small sample size and shortened part 1 trial duration that undermined the power of the study to demonstrate such treatment effects at a significant level.

Discussion

Nusinersen demonstrated a favorable long-term benefit-risk profile in this broad population of individuals with infantile- or later-onset SMA.

SUBMITTER: Acsadi G 

PROVIDER: S-EPMC8248061 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC9932014 | biostudies-literature
| S-EPMC8935309 | biostudies-literature
| S-EPMC8563549 | biostudies-literature
| S-EPMC7127286 | biostudies-literature
| S-EPMC7998943 | biostudies-literature
| S-EPMC8567776 | biostudies-literature
| S-EPMC10605531 | biostudies-literature
| S-EPMC9599672 | biostudies-literature
| S-EPMC8248060 | biostudies-literature
| S-EPMC8320162 | biostudies-literature